Headache最新文献

{"title":"Ipsilateral epistaxis in a patient with episodic cluster headache.","authors":"Juan Fernando Ortiz, Camila D Lopez, Romina Ballagan Escobar, Nicholas J Lannen","doi":"10.1111/head.70207","DOIUrl":"10.1111/head.70207","url":null,"abstract":"","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"2201-2202"},"PeriodicalIF":3.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148880242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hormonal treatments and migraine characteristics across reproductive stages and transition to menopause: A cross-sectional study.","authors":"Laura Gómez-Dabó, Rut Mas-de-Les-Valls, Ane Murillo, Víctor J Gallardo, Marta Torres-Ferrús, Alicia Alpuente, Teresa Mateu, Eulàlia Giné-Ciprés, Edoardo Caronna, Patricia Pozo-Rosich","doi":"10.1111/head.70222","DOIUrl":"10.1111/head.70222","url":null,"abstract":"<p><strong>Background and objectives: </strong>Hormonal treatments (HTs) are widely used among females for contraception and gynecological conditions, yet their impact on migraine phenotype remains incompletely understood. This study aimed to (1) describe HT use in a cohort of females with migraine, (2) assess migraine phenotypes across hormonal status and HT type, and (3) explore menstrual and climacteric symptoms in females with migraine HT users versus nonusers.</p><p><strong>Methods: </strong>A cross-sectional study was conducted including females aged 18-60 years with migraine, diagnosed according to International Classification of Headache Disorders, 3rd edition, criteria who attended a tertiary headache unit in Spain. In December 2024, participants were asked to complete a structured online survey on HT use (combined oral contraceptives, progestogen-only pills, and hormonal intrauterine devices; only considered if stable for ≥3 months), reproductive status (reproductive stage [RS] or menopause transition), and menstrual or climacteric symptoms. Data were cross-checked with medical records and phone interviews. Age- and size-matched analyses compared HT users and nonusers, and comparisons among HT types were also performed.</p><p><strong>Results: </strong>A total of 623 females responded to the survey; 509 were included in the analysis (mean age 44.3 ± 9.2 years), including 86 (17%) current HT users. Overall, migraine phenotype and preventive treatment use were comparable between HT users and nonusers, with no statistically significant differences after adjustment for multiple comparisons (all adjusted p-values > 0.05). Among females in the RS and regular menstrual cycles (n = 78), menstrually-related migraine was highly prevalent (67/78; 86%). In the RS group comparisons (n = 109), no differences according to HT use in migraine characteristics or menstruation-related symptoms were observed (all adjusted p-values > 0.05). Similarly, among females in the menopause transition (n = 42), no differences in migraine phenotype, preventive treatments, or climacteric symptoms were observed according to HT use (all adjusted p-values > 0.05).</p><p><strong>Conclusions: </strong>In this real-world cohort of females with migraine, stable HT was not clearly associated with differences in migraine phenotype or preventive treatment patterns across reproductive stages. Menstrually-related migraine was highly prevalent, and the menopause transition represented a period of vulnerability in a subset of patients. Larger and prospective studies are needed to confirm these findings.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"2090-2102"},"PeriodicalIF":3.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148967915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond pressure: Reframing idiopathic intracranial hypertension in the era of GLP-1 receptor agonists.","authors":"Nik Krajnc, Gabriel Bsteh","doi":"10.1111/head.70150","DOIUrl":"10.1111/head.70150","url":null,"abstract":"","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1947-1949"},"PeriodicalIF":3.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148792227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted liquid chromatography-tandem mass spectrometry profiling of arginine and histidine derivatives in chronic migraine: Discriminatory performance and changes after onabotulinumtoxinA therapy.","authors":"Seyma Dumur, Kadidiatou Diarra, Joudy Sewidan, Julie Jalila Kalmoni, Demet Aygun, Dildar Konukoglu, Hafize Uzun","doi":"10.1111/head.70179","DOIUrl":"10.1111/head.70179","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;This study was conducted to characterize plasma arginine, histidine, 1-methylhistidine, and 3-methylhistidine in chronic migraine and to evaluate their discriminatory ability and association with early clinical response to onabotulinumtoxinA (BoNT-A).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Alterations in nitric oxide- and histamine-related metabolic pathways may contribute to chronic migraine biology and may provide circulating biomarkers for disease stratification and treatment monitoring. Targeted liquid chromatography-tandem mass spectrometry profiling enables precise quantification of candidate amino acids and derivatives implicated in these pathways.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This retrospective secondary analysis was conducted as a case-control study with an embedded uncontrolled pre-post analysis and included 30 adults with chronic migraine receiving BoNT-A and 30 age- and sex-matched healthy controls from Istanbul Atlas University Hospital, based on clinical and laboratory data collected between May 15, 2023, and December 15, 2024. Plasma arginine, histidine, 1-methylhistidine, and 3-methylhistidine were quantified by liquid chromatography-tandem mass spectrometry. In the chronic migraine group, pain intensity (visual analog scale [VAS]) and monthly migraine attack frequency were assessed at baseline and 1 month after BoNT-A. Between-group comparisons and within-subject pre-post comparisons were performed, and exploratory analyses evaluated relationships between metabolite levels and clinical outcomes.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;At baseline, compared with controls, patients with chronic migraine had higher plasma arginine (57.3 ± 13.8 vs. 35.9 ± 10.1 μmol/L; p &lt; 0.001) and 3-methylhistidine (1.0 ± 0.4 vs. 0.7 ± 0.4 μmol/L; p = 0.004), and lower histidine (51.7 ± 10.2 vs. 61.5 ± 6.8 μmol/L; p &lt; 0.001); 1-methylhistidine did not differ significantly (p = 0.217). After BoNT-A, median VAS decreased from 8.0 (7.0-9.0) to 2.0 (0.0-3.0) (p &lt; 0.001) and median monthly migraine attack frequency decreased from 11.0 (6.0-14.8) to 1.0 (0.0-1.8) (p &lt; 0.001). Histidine increased from 54.10 μmol/L (45.27-59.81) to 60.23 μmol/L (57.87-64.45); p = 0.003) whereas 3-methylhistidine decreased from 0.85 μmol/L (0.69-1.23) to 0.66 μmol/L (0.59-0.83); p &lt; 0.001). 1-Methylhistidine did not change significantly, with median values of 5.39 μmol/L (3.41-14.28) at baseline and 6.84 μmol/L (3.36-15.33) at month 1 (p = 0.658). Arginine also did not change significantly with median values of 56.74 μmol/L (46.56-65.95) at baseline and 52.83 μmol/L (44.22-66.30) at month 1 (p = 0.248). Change in histidine was not associated with ΔVAS, and exploratory regression analyses did not identify a robust independent association between baseline variables and pain reduction. In receiver operating characteristic analyses, histidine (area under the curve [AUC] = 0.79) and 3-methylhistidine (AUC = 0.71) showed moderate discrimination, whereas argi","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"2041-2053"},"PeriodicalIF":3.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13653248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148445815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Child abuse and migraine in adulthood: A prospective cohort study spanning 20 years.","authors":"Elizabeth D Handley, Justin Russotti, Rachel Y Levin, Lauren M Hutson, Dante Cicchetti","doi":"10.1111/head.70115","DOIUrl":"10.1111/head.70115","url":null,"abstract":"<p><strong>Objectives: </strong>This study aims to determine the long-term impact of child abuse on the occurrence of adult migraine, to test sex differences associated with this risk, and to examine whether psychiatric disorders are explanatory mechanisms of action.</p><p><strong>Background: </strong>Child abuse and adult migraine have been linked in multiple studies; however, the evidence base is marked by cross-sectional designs and retrospective self-reports of abuse, which may limit conclusions regarding the association.</p><p><strong>Methods: </strong>In a 20-year longitudinal cohort study conducted in upstate New York (wave 1: 1986-2009; wave 2: 2018-2024), we examined associations between Child Protective Service (CPS) documented child abuse and self-reported lifetime and past-year physician-diagnosed migraine in adulthood. We controlled for key demographic and lifestyle variables, as well as depression, anxiety, and post-traumatic stress disorder (PTSD). We also tested sex moderation. Exploratory analyses investigated whether psychiatric disorders mediate the link between child abuse and adult migraine, and whether this mechanism varies by sex.</p><p><strong>Results: </strong>The present sample (N = 305) was 51.1% female and primarily Black (59.4%), with approximately one-third exposed to childhood abuse (34.1%). Females were more likely than males to report past year migraine as diagnosed by a medical professional (26.3% vs. 15.5%). CPS documented child abuse was associated with adult migraine for men but not women, in models adjusted for adult age, income, race, depression, anxiety, PTSD, smoking, and self-reported maltreatment exposure (adjusted odds ratio [aOR]_males = 1.77; 95% confidence interval [CI], 1.09-2.86; aOR_females = 0.68; 95% CI, 0.40-1.16). This finding held when additional covariates were included in sensitivity analyses such as adult retrospective report of child maltreatment, adult sleep quality and body mass index. Depression mediated the association between child abuse and adult migraine for males.</p><p><strong>Conclusion: </strong>Child abuse increases the long-term risk for migraine among males. Given the prevalence of child abuse and the significant public health burden of migraine, understanding how and why child abuse may elevate risk of migraine is critical to informing interventions and policies to improve health and well-being.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"2032-2040"},"PeriodicalIF":3.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13286048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148271385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalized machine learning prediction of next-day migraine persistence using digital headache diary data.","authors":"Ya-Hsiu Tsai, Chen-Lin Chiou, Jun-Jun Lee, Chun-Ming Yang, Kao-Chang Lin, Tain-Junn Cheng, Ja-Hwung Su, Cheng-Hsin Chuang","doi":"10.1111/head.70178","DOIUrl":"10.1111/head.70178","url":null,"abstract":"<p><strong>Objectives/background: </strong>Migraine is a disabling neurological disorder with substantial interindividual variability. Predicting whether an ongoing migraine attack will persist into the following day remains challenging. We evaluated the feasibility and predictive performance of personalized machine learning models for predicting next-day migraine persistence using longitudinal digital headache diary data.</p><p><strong>Methods: </strong>This prospective longitudinal cohort study was designed for prognostic prediction model development. Participants were recruited from two medical centers in Taiwan between February 2023 and October 2023, and each completed a 3-month digital headache diary observation period. Patients with 5-14 monthly headache days were included. Same-day diary records from index migraine days were used to predict next-day migraine persistence. Personalized and generalized models were developed using k-nearest neighbors (KNN), support vector machine, random forest, and eXtreme Gradient Boosting (XGBoost). Model performance was evaluated using discrimination, calibration, and sensitivity analyses.</p><p><strong>Results: </strong>A total of 25 patients were included. Compared with the generalized KNN model, the personalized KNN model achieved significantly higher area under the curve (AUC) (0.83 ± 0.09 vs. 0.63 ± 0.04; ΔAUC = 0.20). Among personalized models, KNN also outperformed support vector machine, random forest, and eXtreme gradient boosting, with ΔAUC values of 0.23, 0.15, and 0.16, respectively; the corresponding Holm-adjusted p-values were <0.001, 0.003, and <0.001. The personalized KNN model showed the lowest Brier score (0.13 ± 0.04), with a calibration intercept of 0.08 and calibration slope of 0.80. Ablation analysis indicated that the KNN model performance was most sensitive to the removal of pain intensity, menstrual cycle status, perceived medication effectiveness, and pain location, with pain intensity showing the largest effect.</p><p><strong>Conclusion: </strong>Personalized machine learning models based on digital headache diary data may feasibly predict next-day persistence of ongoing migraine. Larger external validation studies are needed to confirm model generalizability and clinical applicability.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"2066-2077"},"PeriodicalIF":3.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13653240/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148455621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity, fasting, and chronic migraine: Can semaglutide disrupt the vicious cycle?","authors":"Hilmi Berkan Abacıoğlu, Murat Kara, Levent Özçakar","doi":"10.1111/head.70209","DOIUrl":"10.1111/head.70209","url":null,"abstract":"","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"2199-2200"},"PeriodicalIF":3.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148880190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceived comfort with migraine treatments and control of migraine symptoms: Results from the Headache Assessment via Digital Platform in United States study.","authors":"Kevin M Spiegler, Ali Ezzati, Kristina M Fanning, Ryan Bostic, Alexandre Urani, François Cadiou, Richard B Lipton, Angeliki Vgontzas","doi":"10.1111/head.70165","DOIUrl":"10.1111/head.70165","url":null,"abstract":"<p><strong>Objective: </strong>This study was conducted to identify patient characteristics and medication factors associated with perceived comfort with migraine treatments and control of migraine symptoms.</p><p><strong>Background: </strong>Patient perceptions of migraine treatment influence adherence and outcomes, yet little is known about their underlying drivers. Our study objective was to identify clinical features of migraine associated with comfort and perceived control of symptoms, and medication classes associated with higher patient comfort and efficacy.</p><p><strong>Methods: </strong>Participants in the Headache Assessment via Digital Platform in United States (HeAD-US) study completed a cross-sectional survey on demographics, migraine burden, mood, disability, and medication use between September and November 2023. Comfort and control were defined using corresponding items from the Migraine Treatment Optimization Questionnaire and categorized as \"high\" or \"low.\" We compared patient characteristics, clinical features, and medication classes by reported comfort and control.</p><p><strong>Results: </strong>Among 5717 participants (mean age, 41.7 ± 13.0 years; 92.1% female), 58.5% reported high comfort with migraine treatments, whereas only 27.5% reported high control of migraine symptoms. High comfort was associated with fewer monthly headache days (mean, 9.9 vs. 14.2; p < 0.001), lower migraine symptom severity (median Migraine Symptom Severity Score 18 vs. 19; p < 0.001), and lower disability (Migraine Disability Assessment Score, severe: 72.7% vs. 91.2%; p < 0.001) and mood symptom scores (Patient Health Questionnaire-4 severe: 9.5% vs. 21.0%; p < 0.001), as well as income, education, and employment status. High perceived control showed similar associations with monthly headache days (mean, 9.0 vs. 12.7; p < 0.001), migraine severity (median Migraine Symptom Severity Score, 18 vs. 19; p < 0.001), disability (severe: 66.0 vs. 85.8; p < 0.001), and mood symptoms (severe: 7.6 vs. 16.9; p < 0.001), and was associated with employment status but not income or education. Among those on monotherapy, gepants and triptans were associated with higher comfort and efficacy than over the counter medications or opioids/barbiturates/ergots. For preventive therapy, β blockers and botulinum toxin were associated with the lowest perceived comfort and efficacy.</p><p><strong>Conclusion: </strong>Perceived comfort and control were linked to headache frequency, severity and disability, and mood symptoms. Medication class use influenced perceptions, with gepants and triptans rated most favorably. These findings underscore the importance of incorporating patient perspectives into treatment planning, with particular attention to mood, disability, and choice of medication.</p>","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"2103-2116"},"PeriodicalIF":3.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148602282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A guide to writing and publishing effective plain language summaries in Headache.","authors":"Meghan Piccinin, Robert C Gibler, Jenn Vallimont","doi":"10.1111/head.70203","DOIUrl":"10.1111/head.70203","url":null,"abstract":"","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"1953-1955"},"PeriodicalIF":3.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148911728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to \"American Headache Society 68th Annual Scientific Meeting June 4-7, 2026, Orlando, Florida\".","authors":"","doi":"10.1111/head.70198","DOIUrl":"10.1111/head.70198","url":null,"abstract":"","PeriodicalId":12844,"journal":{"name":"Headache","volume":" ","pages":"2203-2205"},"PeriodicalIF":3.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148850382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}